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ANTIMALARIAL DRUG EVALUATIONS: 
NAMRU-2 AND INDONESIAN PARTNERSHIP 
WJR Taylor*, Thomas L. Richie*, Emiliana Tjitra** 
EVALUASI OBA T ANTIMALARIA: 
KEMITRAAN NAMRU-2 DAN INDONESU 
Meningkatnya insiden malaria di beberapa daerah tertentu terutama di Indonesia Bagian Timur 
disebabkan antara lain : P. falciparum telah resisten terhadap beberapa obat antimalaria, 
ditemukannya P. vivax resisten klorokuin, dun belum tersedianya vaksin yang efektiJ Sehubungan 
dengan ha1 tersebut, dilakukanlah evaluasi obat antimalaria yang perlu dipertimbangkan dalam 
peningkatan pelaksanaan program. 
Obat antimalaria mejlokuin, halofantrin dun beberapa derivat qinghaosu (artesunat dun 
artemeter) telah diuji coba klinik di Indonesia, dan memberikan efikasi yang cukup baik walaupun 
perlu dipertimbangkan kemungkinan efek samping dun resistensi atau rekrudesensi yang mungkin 
terjadi serta harganya yang relatifmasih mahal. 
Obat antimalaria baru yang direncanakan akan diuji coba klinik adalah azithromycin, derivat 
primaquine WR 238605, atovaquone dun derivat qinghaosu lain. 
Dasar pengembangan pengobatan malaria adalah sebagai berikut : 
1. Meningkatkan atau memperbaiki efikasi pengobatan malaria tanpa komplikasi yaitu dengan 
mengembangkan kombinasi atau regimen obat antimalaria yang tersedia di Indonesia (klorokuin 
dun tetrasiklin/doksisiklin) atau dengan mempersiapkan obat antimalaria baru (derivat qinghaosu, 
atovaquone, azithromycin dun WR 238605). 
2. Mencari obat antimalaria baru alternatifyang efekt~ysebagai obat penyelainat untuk pengobatan 
malaria dengan komplikasi. 
Dengan melakukan evaluasi obat antimalaria in;, akan didapat data efikasi dun keamanan yang 
dapat membantu Departemen Kesehatan untuk menentukan obat pilihan di Indonesia. Selain itu juga 
dapat ikut membantu mcnanggulangi masalah malaria di dunia. 
* U.S. Naval Medical lwsearch IJnit No. 2, Jakarta, Indonesia 
** Communicabie Dlseases Research Centre, NIHRD, Ministry of Health, Jakarta, Indonesia. 
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INTRODUCTION 
The Naval Medical Research Unit Number 
2 (NAMRU-2) throughout its twenty five year 
history has worked closely with several 
Indonesian institutions and the Ministry of 
Health to carry out malaria research in different 
parts of Indonesia. These institutions include: 
the Center for Health Research and 
Development (Badan Litbangkes), the Center 
for Disease Control and various Provincial 
Health Authorities. Tlus article will outline the 
antimalarial drug evaluation program being 
considered between NAMRU-2 and the 
Indonesian Ministry of Health. 
Recent evidence suggests that maiaria 
incidence is increasing in certain parts of 
Indonesia but is particularly problematic in the 
eastern parts of the country where antimalarial 
drug resistance has been recognized for some 
time for P. fa l~ i~arurn"~.  In Irian Jaya (also in 
adjacent Papua New Guinea) and in Nias, 
northern Sumatera, there is strong evidence that 
chloroquine resistant P. vivax is contributing to 
the malaria p r~b lem~.~ .  
CURRENT EXPERIENCE WITH ANTI- 
MALAFUAL DRUGS IN INDONESIA 
The current medications for treatment of 
malaria blood stage infection approved for use 
in Indonesia are chloroquine, pyriniethaminei 
sulfadoxine (Fansidar"), and quinine. with 
primaquine approved for treatment of liver 
stages of P. vivnx and sexual stages of 1'. 
falciporutn. Mefloquine, halofantrine and 
artemether have been emluated in limited trials 
(see Table 1 and Table 2)  but are not currently 
approved for widespread use. Each of these 
zgsnts is associated with one or another 
probleln related to toxicity or resistance. 
Chloroquine resistance is high and 
widespread throughout the archipelago but 
concentrated in the east. Combination therapy 
with primaquine may overcome some 7f the 
resistance seen in P. vivax (K. Baird, p-rsonal 
communication) but this regimen must be 
completely evaluated and the problem of quick, 
inexpensive and accurate G6PD testing, 
3-es-onmended for the use of primaquine, 
remains to be solved. Fansidarm resistance is 
also con~rnon'.'~ and the treatment is 
occasionally associated with the Stevens- 
Johnson syndrome in those individuals with 
sulfa drug sens~tivity. Quinine, while effective, 
has side effects that make it unpalatable to 
many patients, resulting in poor compliance and 
subsecjuent treatment failure. Quinine 
resistance is increasingly reported in SE Asia. 
Anecdotal reports of mefloquine 
prophylaxis failures in eastern Indonesia and of 
in vitro resistance (K. Baird, personal 
comn~unication andii.'*) are worrisome and 
suggest that its utility and that of the related 
compollnd, halofantrine, may be short-lived. 
Mefloquine has been associated with several 
cases of acute psychosis as well as vertigo and 
sleep disturbances that make it intolerable for 
some patients. Halofantrine, given as a three 
dose regimen over 12 hours, is effective against 
most strains of falciparum malaria; however, 
non-immunes often require a second course of 
treatment, as evidenced by the recrudescent 
parasitemia seen in patients treated with 
halofantrine in Halofantrine has 
poor bioavailability. It causes significant 
lengthening of the QT interval of the ECG 
which has lead to a few cardiac deaths in 
predisposed persons. In addition, malaria 
strains resistant to mefloquinc arc often also 
resistant to halofantrine. causing the drug to be 
of limited usefulness for treating P. falcj~~nrutn 
in areas where mefloquine resistance bas 
developed. 
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Table 1: Prophylaxis 
. Summary of currently licensed and unlicensed antimalarial prophylactic drugs and their efficacy in RI. 
1. Approved for indications other than malaria prophylaxis or treatment. 
2. Approval for treatment of liver stages of P. vivax (radical cure) and treatment of sexual stages (garnetocytes) of P. falciparum. 
3. Approval for treatment of liver stages of P. v i v a  (radical cure). 
4 .  Studies by NAMRU in Inan Jaya. 
5. Not yet tested in Indonesia for antimalarial prophylaxis. Clinical trial planned. 
6. Adult dose; source: JJMS (Indonesia Index of Medical Specialties, 1995), except mefloquine (British National Formulary, 199 ) 
t 
DRUG 
Weekly chloroquine 
(300 rng base) 
Weekly metloquine 
(250 mg) 
Weekly pynrneth- 
arninelsulfadoxine 
(25 mg/SOO mg) 
Daily doxycycline 
(100 mg) 
Daily primaquine 
(30 base) 
Daily azithromycin 
(250 mg) 
ADVANTAGES 
widely available; can be 
used in pregnancy, breast 
feeding & children; cheap 
excellent efficacy4 
moderate efficacy; cheap 
excellent efficacy4 
good efficacy ; widely 
available; moderate price 
promising efficac? ; well 
tolerated; can be used in 
children, probable use in 
pregnancy1 breast feeding 
APPROVAL 
F3 
Yes 
No 
No 
No 
No2 
No 
STATUS 
OTHER' 
REMARKS 
DISADVANTAGES 
poor efficacy4; unsuitable in 
epilepsy, opthalmic toxicity, regular 
opthalmic review may be needed for 
long-term use 
rare CNS & cardiac toxicity, 
contraindicated in pregnancy & 
breast feeding, children < 15kg, 
expensive 
Stevens Johnson syndrome, bone 
marrow depression, contraindicated 
in pregnancy & breast feeding of 
G6PD deficient infants 
contraindicated in pregnancy & 
children < 8 
contraindicated in pregnancy & 
G6PD deficiency 
expensive 
MALARIA 
USA 
Yes 
Yes 
Yes 
Yes 
No3 
No 
RI 
Yes 
No 
No 
Yes 
NO 
Yes 
COST 1 WEEK6 
Rp. 200 
6.000 
600 
2.250 
1.400 
45.000 
USA 
Yes 
No 
No 
Yes 
NO 
Yes 
8 
Table 2: Treatment: Summary of currently licensed & unlicensed drugs used for the treatment of malaria and their efficacy in RI. 
1. Approved for indications other than malaria prophylaxis or treatment (doses, formulatiom may differ). 5. Doxcycycline 
2. Studies by NAMRU in Irian Jaya. 6. F'ynmethamine/sulfadoxine 
3. Studies by LITBANGKES. 
4. Not yet tested in Indonesia for antimalarial treatment. Clinical trial planned. 
DRUG 
Chloroquine 
=CQ (600 d l  d2, 
MO mg d3 
CQ + prima- 
quine (60 mg 
base X 3d) 
CQ + doxy' 
(100mgll2hx7d) 
Quinine (600 
mg/R hr x 7d) 
Quinine (X 4d) 
+ doxycycline 
(x 10d) 
Mefloquine 
(1250 mg) 
Halofantrine 
(500 mgi6 hr 
x 3) 
PIS"75 mg 
i 1500 mg) 
Artemisinin & 
derivatives 
Atovaquone + 
F'roguanil(500 
mgil mg X 3d) 
Cost I 
course 
Rupiah 
500 
1.700 
3.300 
6.300 
7.600 
36.000 
23.100 
2.520 
7.000 
81.000 
b 
ADVANTAGES 
cheap, widely available, used in 
pregnancy, breast feeding, 
children 
improved efficacy against vivax 
over chloroquine alone2 
improved efficacy over 
chloroquine alone in Afiica 
good efficacy, rapidly acting 
excellent eff ica4 
good efficacy 
good efficacy, 
well toleratedz3 
moderate efficacy 
good efficacy', rapidly acting. 
well tolerated 
excellent efficacy against 
falciparum, well tolerated, 
proguanil safe in pregnancy 
REMARKS 
DISADVANTAGES 
, 
falciparum resistance widespread2', 
vivax resistance in Irian Jayaz & Niasz 
primaquine contraindicated in G6PD deficiency, breast 
feeding & pregnancy 
efficacy unknown in Indonesia4, doxycycline 
contraindicated in breast feeding, pregnancy & 
children < 8 
poorly tolerated, poor compliance 
better tolerated than quinine alone for 7 days but still 
with poor compliance, quinine contraindicated in optic 
neuritis, tinnitus, hemoglobinuria, pregnancy but 
benefit of treatment outweighs risk 
expensive, rare CNS & cardiac toxicity, 
contraindicated in pregnancy, breast feeding, children 
< 15kg. 
expensive, must be taken on empty stomach, rare 
cardiac toxicity (deaths), contraindicated in pregnancy, 
breast feeding, cardiac disease associated with a 
prolonged QT interval, children < lOkg 
Stevens Johnson syndrome, bone marrow depression, 
contra-indicated in pregnancy & breast feeding of 
G6PD deficient infants 
significant recrudescence when used alone, severe 
neurotoxicity in primates with higher doses 
efficacy unknown in Indonesia; atovaquone: limited 
data on use in pregnancy but may be safe; expensive 
APPROVAL 
MALARIA 
STATUS 
OTHERL 
RI 
Yes 
Yes 
No 
Yes 
No 
No 
No 
Yes 
No 
No 
RI 
Yes 
No 
(prima 
quine) 
Yes 
(doxy) 
Yes 
No 
No 
No 
Nd 
No 
No 
USA 
Yes 
No 
No 
Yes 
No 
Yes 
Yes 
Yes 
No 
No 
USA 
Yes 
No 
(prima 
quine) 
Yes 
(doxy) 
Yes 
No 
No 
No 
No 
No 
Yes 
(atova- 
quone) 
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Preliminary studies using artemether and 
artesunate indicate that, as in other parts of the 
world, there is a significant rate of 
recrudescence following initial parasite 
~learance'~. '~. In addition, neurotoxicity has 
been documented in rats, dogs and monkeys 
receiving artemether and arteether, raising the 
possibility that repeated dosing in humans could 
cause brain stem injury"-'". For this reason, 
development of arterni-snin derivatives su-21 as 
artemether is concentrating on their value for 
treating severe, life-threatening P. Jalcrparrr?r 
infections. 
DRUG DEVELOPMENT 
Because of emerging drug resistance 
problems, toxicity of available agents and the 
lack of an efficacious vaccine on the horizon, 
Indonesia has reason to be on the cutting edge 
of antimalarial drug evaluations. For the same 
reasons, the US Navy and NAMRU-2 would 
like to evaluate antimalarial drugs in areas of 
__ _ 
known drug resistance in Indonesia once those 
agnts  have been evaluated for safety of use in 
human subjects. A well developed program of 
antimalarial drug development will be of great 
use to the Indonesian Center for Disease 
Control in mapping resistance patterns 
throughout the archipelago; and in making 
recommendations for prevention and treatment. 
The US Navy's antimalarial drug 
development program is closely coordinated 
with that of the US Army. Antimalarial drugs 
are discovered and developed largely through a 
cooperative research program involving the 
Walter Reed Army Institute of Research 
(WRAIR), the World Health Organization 
(WHO) and various pharmaceutical firms 
(Roche, SmithKline Beecham, Burroughs 
Wellcome). WRAIR has conducted one of the 
largest drug screening programs in the world 
having processed nearly 300,000 compounds 
searching for antimalarial activity. Drugs 
developed by the WRAIRIWHO program to 
address the growing problem of multi-drug 
resistant P. falciparum malaria include 
mefloquine and halofantrine. Drugs currently 
under development include the antibiotic 
azithromycin, the artemisinin (qinghoasu) 
derivative arteether, the anti-protozoal agent 
atovaquone, and the as yet unnamed primaquine 
derivative W 3 8 6 0 5 .  
Cornpounds under development as 
,intimalarials are extensively screened for 
toxicity prior to evaluation in the field. Of the 
four compounds listed above, azithromycin and 
atovaquone are licensed in the United States for 
non-malarial indications, so that the usual 
preclinical and Phase I safety data have been 
supplemented by extensive experience in the 
public sector. Unlicensed compounds such as 
arteether and W 3 8 6 0 5  are tested for safety 
prior to any consideration of field trials. 
Following animals studies, this initial human 
volunteer testing takes place in the United 
States, primarily in US soldiers at Fort Detrick, 
Maryland. Once the compound is known to be 
safe and effective in mosquito challenge trials in 
soldiers, it is ready for efficacy studies where 
the disease occurs naturally. The US military 
overseas laboratories and WHO collaborators 
develop field trials to demonstrate the drug's 
actual utility in the treatment or prophylaxis of 
malaria. The best field-applicable drug regimen 
is defined through testing in more than 1000 
individuals in several different sites world-wide. 
Then pharmaceutical firrns become involved in 
the formulation and mass production of the new 
antimalarial drug for the world market. 
Continual drug discovery and development 
is necessary due to the rapid development of 
drug resistance. Malaria parasites are able to 
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devise metabolic means of escaping drug killing 
through the progressive selection of increasingly 
drug tolerant strains. In Thailand, the average 
useful life time of a new antimalarial drug is 5 
to 10 years. Spread of resistant strains from one 
part of the world to another occurs rapidly 
through international travel by students, 
soldiers, rehgees and other persons carrying 
malaria parasites into areas w~th  receptive 
mosquitoes. Wise drug use policies in one area 
can be overturned quickly when new drug 
resistant parasites are introduced from other 
areas. 
The use of new antimalarials has caused 
concern in Indonesia in the past because of the 
cost of some of these agents. These drugs are 
not commercially attractive due to the expense 
of development ($US 100 to 200 million) and 
the relatively small returns expected on this 
investment. Without the involvement of the US 
Department of Defense and the WHO, it is 
unlikely that any new drugs would be developed 
against malaria due to lack of financial 
incentives. However, through participation in 
clinical drug trials, countries such as Indonesia 
can ensure that drugs work against their 
particular strains of malaria and gain early 
access to new products usually on favorable 
terms negotiated with the pharmaceutical 
developer. 
FUTURE PLANS 
New drugs expected in the %lure include 
the compounds summarized below. NAMRU 
and Badan Litbangkes plan to evaluate an 
inexpensive combination of chloroquine and 
doxycycline that obviates the problem of GGPD 
testing and uses products already approved in 
Indonesia. It is hoped that this trial will be 
followed by the antibiotic azithromycin for 
prophylaxis and WR238605 for prophylaxis 
and/or radical cure of incubating tissue 
infections. Also under consideration is the 
highly promising combination of atovaquone- 
proguanil for treatment. Azithromycin is 
already licensed for use in Indonesia, Europe 
and the United States and atovaquone and 
propanil are licensed as individual agents (not 
as a combination) in Europe and the United 
States. Azithromycin and atovaquone are 
widely used to treat other infections and have 
been found to be safe. Proguanil is probably the 
safest of a!l the antimalarial drugs currently in 
use and like chloroquine can be given to 
pregnant women and infants. 
1. Tetracycline and doxycycline appear to 
have significantly improved the eficacy of 
quinine in The emergence of 
chloroquine resistant P. vivax in Irian Jaya 
presents a treatment problem. Fansidar 
works poorly for P. vivax and quinine is not 
well tolerated. II has been observed that 
private physicians are treating malaria in 
Irian Jaya with standard chloroquine and 7 
days of doxycycline or tetracycline. It is 
proposed that patients with unconlplicated 
1'. Jalciparunz and P. vivax malaria 
presenting for treatment or found on 
screening will be asked to participate in a 
hospital based trial of doxycycline plus 
chloroquine if they have no signs or 
symptoms suggesting severe malaria. All 
will be randomized to receive standard 
therapy with chloroquinc for three days 
alone or cliloroquine for three days plus 
doxycyclinc for seven days or, only for 
those with low parasiten~ia, doxycycline 
alone for seven days. The main objective of 
this study is to determine if doxyeycline 
significantly improves the efficacy of the 
standard chloroquinc lreatrnent o f  P. itii>rrx 
and P. fnlctparunr malaria in Irian Java. If 
the combination is shown to be efficacious, 
dose ranging studies tvill follow. 
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2. Azithromycin is a macrolide antibiotic 
related to erythromycin that is long-acting 
and has good tissue penetration. It is 
currently licensed and widely used for 
bacterial, mycoplasma and chlamydia 
infections in the US and Europe, with 
particular application to respiratory illness. 
It is licensed for use for similar indications 
in Indonesia. Azithromycin appears to 
have significant prophylactic activity 
against falciparum malaria, with evidence 
of both tissue and blood schizonticidal 
effects. It is unclear what the optimum 
regimen should be, but phase I1 human 
prophylaxis trials are currently underway in 
Kenya. Azithromycin's superiority to 
doxycycline would appear to be its safety in 
children and pregnant women (its level of 
safety and tolerance appear to be similar to 
that of erythromycin). It is hoped that we 
will be able to evaluate azithromycin's 
efficacy in Indonesian soldiers in 1996. 
Azithromycin may also be useful for the 
empiric therapy of children presenting with 
fever and respiratory symptoms in 
malarious areas. Because the drug appears 
to be effective against both malarial and 
respiratory illness, it may prove beneficial 
in areas lacking the capability for 
laboratory identification of respiratory and 
protozoal pathogens. 
3. WR 238605 is an analogue of primaquine 
with a very long half life. It is 
approximately 10 times more effective than 
primaquine in treating the liver stages of 
monkey malaria in both radical curative 
and causal prophylactic modes. WR 
238605 is very well tolerated in humans up 
to at least 600 mg in a single dose. 
Although no toxicity has been seen in 
humans, it is expected from animal studies 
that WR 238605 will cause hemolysis in 
G6PD deficient individuals and also 
methemoglobinemia, similar to 
primaquine. It has recently been tested for 
causal prophylaxis in a volunteer challenge 
study at WRAIR and those results are 
expected soon. WR 238605 will probably 
replace primaquine as a radical curative 
drug and will have profound prophylaxis 
and public health applications. If WR 
238605 lives up to its full promise, it is a 
drug which, when used in combination with 
an effective vaccine, may permit the 
eradication of malaria. 
4. Atovaquone is a new class of antimalarial 
drug. It is currently licensed for the 
treatment of Pneumocystis and Toxoplasma 
in AIDS patients, in whom dosages several 
times those used for malaria are routine. 
Atovaquone cannot be used alone for 
malaria due to the rapid evolution of drug 
resistance. However, it is extraordinarily 
effective against multi-drug resistant P. 
falciparum when combined with proguanil 
or tetracycline. Its current regimen is 1000 
mg atovaquone and 400 mg proguanil 
given once a day, for 3 days. Phase I11 
trials are currently underway in Thailand, 
Zambia and Kenya and will start soon in 
Brazil. Preliminary results suggest an 
excellent record of eficacy for treating drug 
resistant P. falciparurn malaria. The drug 
combination also appears to be very safe 
and well tolerated. However, its expense 
may limit broad application in Indonesia at 
the current time and testing is on hold. 
5.  Development of artemisinin derivatives as 
standard treatment for uncomplicated 
malaria is currently held up due to the 
severe neurotoxicity demonstrated in rats, 
dogs and monkeys"-'s. While receiving 
doses higher than would normally be given 
for malaria treatment, these animals 
developed extensive brain stem lesions, 
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leading to neurological deficits, and, at 
higher doses, to death. While neurological 
damage has not been reported in humans, 
there is concern that repeated treatment, 
during the course of childhood for example, 
could lead to brain stem injury. Studies at 
WRAIR are currently underway to ident* 
which artemisinin derivatives cause this 
syndrome, whether the chemical structure 
responsible for the toxicity is linked lo 
antimalarial activity (or whether the two 
can be separated, permitting the design of 
non-neurotoxic derivatives), and whether 
repeated smaller doses has a cumulative 
toxicity similar to that seen acutely with 
higher doses. Pending the results of these 
studies, many experts are recommending 
that the use of artemisinin derivatives be 
restricted to the treatment of severe disease, 
for which it is at least effective as quinine 
and for which the toxicity risks are 
overbalanced by the risks presented by 
malaria itself. 
CONCLUSIONS 
To summarize, the drug development 
program is designed with two principal goals. 
The first is to develop new drugs that wili 
improve efficacy in the treatment of 
uncomplicated malaria or in the prophylaxis of 
malaria. Efforts in this direction can be divided 
into two parts. First, we are searching for novel 
combinations of drugs currently available in 
Indonesia. Examples are primaquine + 
chloroquine to treat chloroquine resistant P. 
vivax, doxycycline + chloroquine to treat both 
P. vivax and P. falczparum. and daily 
phimaquine for prophylaxi4 of both P. vivax and 
P. falciparum. As a second route to this goal, 
we wish to evaluate new agents that are either 
approved Ibr antimalarial ~ndicat~ons in other 
countries or currently under development. 
Three new drugs or drug combinations that 
appear particularly promising because of good 
safety records and expectation of high efficacy 
include azithromycin, WR238605. and 
atovaquone / proguanil. A second major goal is 
evaluating new agents for the treatment of 
severe and complicated disease. Artemisinin 
derivatives are potentially excellent alternatives 
to parenteral quinine and are currently under 
evaluation in northern Sulawesi as life-saving 
drugs for the treatment of severe malaria. 
By evaluating these drugs, first and 
foremost the Ministry of Health will be in a 
position to make drug choice recommendations 
that are based on known eficacy and tolerance 
data in Indonesia. Thc Center for Disease 
Control will be positioned to respond wisely to 
the emergence of epidemics or new patterns of 
resistance to the antimalarials currently in use. 
In addition, Indonesia will gain recognition as a 
committed member of the international 
community seeking to overcome the problem of 
malaria. 
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